Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Aschaffenburg – page 68

1 096 clinical trials in Aschaffenburg, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Aschaffenburg at a glance
1 096
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 096 trials in Aschaffenburg

Open in trial search

Study of Venetoclax and Blinatumomab for Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Goethe University Frankfurt

Hidradenitis

Not recruiting

Study of lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on De-escalated Induction Therapy with Methotrexate, Cytarabine, Thiotepa, and Rituximab for Newly Diagnosed Primary CNS Lymphoma Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Klinikum Der Landeshauptstadt Stuttgart gKAöR

Breast cancer

Not recruiting

Study on Palbociclib and Drug Combination for Patients with Hormone Receptor Positive, HER2-Positive Metastatic Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Alliance Foundation Trials LLC

Fallopian tube cancer+3

Not recruiting

Study on Mirvetuximab Soravtansine and Carboplatin for Patients with Recurrent Ovarian Cancer Eligible for Platinum-Based Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AGO Research GmbH

Colitis ulcerative

Not recruiting

Study on the Effects of Fecal Microbiome and Fecal Microbiome Filtrate Capsules for Patients with Active Ulcerative Colitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Metronidazole
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Systemic candida

Not recruiting

Study of Recombinant Interferon-Gamma 1b Combined with Standard Treatment for Patients with Candidemia: Safety and Effectiveness Evaluation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Stichting Radboud University Medical Center

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study comparing chemotherapy with or without radiation therapy in patients with resectable gastroesophageal junction cancer using docetaxel, oxaliplatin, fluorouracil and calcium folinate

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Heidelberg University

Cholangiocarcinoma+1

Not recruiting

Study on Gemcitabine and Cisplatin for Patients After Surgery for Bile Duct or Gallbladder Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:University Medical Center Hamburg-Eppendorf

Short-bowel syndrome

Not recruiting

Study on the Long-Term Safety and Effectiveness of Glepaglutide for Patients with Short Bowel Syndrome

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glepaglutide
  • Sponsor:Zealand Pharma A/S

Major depression+1

Not recruiting

Study on Aticaprant and Antidepressant for Preventing Relapse in Adults with Major Depressive Disorder and Anhedonia

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Aticaprant
  • Sponsor:Janssen Cilag International

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany

Clinical research in Aschaffenburg

What the registry says about research in the country

01 Hematologic Oncology

Groundbreaking research focusing on acute myeloid leukemia and chronic lymphocytic leukemia, evaluating novel therapeutic approaches including targeted therapies and combination treatments. Studies examine innovative drug combinations to improve patient outcomes in various blood cancers.

  • FLT3-mutation targeted therapies
  • Chemotherapy optimization
  • Novel drug combinations

Multiple trials investigating treatments for both newly diagnosed and relapsed/refractory patients.

02 Breast Cancer Research

Advanced studies in hormone receptor-positive breast cancer, particularly focusing on metastatic disease. Investigations include new combination therapies and targeted treatments for patients with specific genetic mutations.

  • ESR1-mutation treatments
  • CDK4/6 inhibitor combinations
  • Endocrine therapy resistance

Research emphasizes personalized treatment approaches based on molecular profiles.

03 Respiratory Medicine

Innovative research in severe asthma treatment, particularly focusing on patients with eosinophilic phenotype. Studies evaluate new biological therapies and compare their efficacy with existing treatments.

  • Anti-IL-5/5R therapy
  • Long-term efficacy studies
  • Phenotype-specific treatments

Trials aim to improve long-term management of severe respiratory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.